

## LeenLife Pharma International Inc.

Suite 380 - 580 Hornby Street  
Vancouver, B.C., V6C 3B6



---

### NEWS RELEASE

---

## LeenLife Pharma International: Corporate Updates

April 13, 2017

CSE - LLP

**Vancouver, B.C. – LeenLife Pharma International Inc.** (the “Company”) is holding its 2017 Annual General Meeting on June 8, 2017. The record date will be May 8, 2017. All shareholders of record as of May 8, 2017 are entitled to attend and vote. If you are unable to attend the annual general meeting, you can vote by proxy. Proxy forms are available from the Company, your broker or financial intermediary.

The Company previously entered into an agreement with LeenLife Pharma S.A., a company incorporated under the laws of Poland (“LeenLife SA”) and its shareholders/management (the “Vendors”) whereby the Company issued 12,232,788 common shares (the “Acquisition Shares”) in the names of the Vendors, but that such shares were held back and not delivered until the Company was satisfied that it was provided effective control of LeenLife SA including pertinent information in exchange for 90% control of this company ( the “Transaction”).

Due to the failure of the Vendors and the management of LeenLife SA in Poland satisfying the essence of the Transaction by delivering control of this Polish company with operating documents to the Company, and having refused to co-operate with the Company with such matters as allowing an audit of the records of this Polish company by a major international audit firm engaged by the Company, having offices in Canada and Poland, as required to satisfy the Company's regulatory requirements, the Transaction has been repudiated by the actions of the Vendors. As the transaction has been repudiated, a liability which would have been created from the receipt of the shares from the Company to the Vendors causing a tax liability of \$563,044 is no longer applicable. This amount was written off in previous financial statements.

The Company returned to treasury and cancelled the Acquisition Shares and returned the original LeenLife SA shares. With the return to treasury and cancellation of these 12,232,788 common shares the Company now has a total of 34,015,318 issued and outstanding common shares.

Further to this matter, on the basis of funds advanced by the Company to LeenLife SA and its suppliers, as provided for by the laws in Poland, the Company has been issued additional shares of LeenLife SA, in the name of the Company and changed the chairperson to gain control of LeenLife SA. The Company has received court approval in Poland for the actions taken by the Company and awarded control of LeenLife SA by endorsing share issuances, the appointment of the new chairperson and dismissed all claims by the Vendors.

## LeenLife Pharma International Inc.

Suite 380 - 580 Hornby Street  
Vancouver, B.C., V6C 3B6



---

### NEWS RELEASE

---

The Company is currently customizing the technology for entry into the markets of Canada and the United States. This will provide the Company with proprietary technology and lower the cost of production. The Company has been focussed on Poland and is preparing for entry to Canada and the United States. According to various marketing reports 50% of future world sales of omega products will be in North America, and 25% in Europe.

For more information, please contact:

Stan Lis, CEO

Tel: 604 764-0518

E-mail: [slis@leenlifepharma.com](mailto:slis@leenlifepharma.com)

### Forward-looking Information

*Certain statements included in this press release constitute forward-looking information or statements (collectively, "forward-looking statements"), including statements that address the Transaction and the meeting of shareholders and those identified by the expressions "anticipate", "believe", "plan", "estimate", "expect", "intend", "may", "should" and similar expressions to the extent they relate to the Company or its management. The forward-looking statements are not historical facts but reflect current expectations regarding future results or events. These forward-looking statements are based on current expectations and various estimates, factors and assumptions and involve known and unknown risks, uncertainties and other factors. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Company will operate in the future, anticipated costs and the ability to achieve goals.*

*While such estimates and assumptions are considered reasonable by the management of the Company, they are inherently subject to significant business, economic, competitive and regulatory uncertainties and risks. Forward-looking statements are subject to a variety of risks and uncertainties, which could cause actual events, level of activity, performance or results to differ materially from those reflected in the forward-looking statements, including, without limitation: (iii) risks related to cost estimates and the potential for unexpected costs and expenses; (v) that the Company may fail to receive necessary licences and permits to operate its business; (vi) that environmental laws and regulations may become more onerous; (vii) that the Company may not be able to raise additional funds when necessary; (ix) foreign government risks, including risks related to accidents, equipment breakdowns, labour disputes or other unanticipated difficulties with or interruptions in the business; (x) competition; (xi) changes in laws and regulations; (xii) the uncertainty of profitability based upon the Company's history of losses; (xiii) risks related to environmental regulation and liability; (xvi) risks related to the outcome of legal actions; (xvii) political and regulatory risks associated with operating in Poland; (xix) risks related to current global financial conditions; and (xx) other risks and uncertainties related to the Company's prospects, assets and business strategy. These risks, as well as others, could cause actual results and events to vary significantly.*

*Readers should not place undue reliance on the Company's forward-looking statements, as the Company's actual results, performance or achievements may differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements if known or unknown risks, uncertainties or other factors affect the Company's business, or if the Company's estimates or assumptions prove inaccurate. Therefore, the Company cannot provide any assurance that such forward-looking statements will materialize. Factors that could cause actual results to differ materially from those in forward looking statements include, the timing and receipt of government, court and regulatory approvals, and continued availability of capital and financing and general economic, market or business conditions, loss of key directors, employees, and consultants, litigation, failure of counterparties to perform their contractual obligations and fees charged by service providers. The forward-looking statements included in this news release are made as of the date hereof and the Company disclaims any*

**LeenLife Pharma International Inc.**

Suite 380 - 580 Hornby Street  
Vancouver, B.C., V6C 3B6



---

**NEWS RELEASE**

---

*intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities laws.*